Rush University Medical Center

Rush University Medical Center Surpasses 100,000 COVID-19 Tests

Large-scale testing made possible by Clinical Microbiology Laboratory team’s work

Newswise — Testing has been one of the top challenges — and top priorities — for hospitals and health systems across the country during the COVID-19 pandemic. Since March, Rush University Medical Center has been a leader in the Chicago area in developing, expanding and evolving in-house testing efforts. 

On Friday, Nov. 13, the Medical Center performed its 100,000th test for COVID-19. This milestone would have not been possible if not for the hard work and scientific skill of Rush’s Clinical Microbiology Laboratory team, which took on the crucial assignment of developing an in-house test for SARS CoV-2, the virus that causes COVID-19, at the beginning of the pandemic and later implemented more expansive testing methods quickly.

Launched on March 16, the Medical Center’s in-house test for COVID-19 was developed in less than two weeks, an effort led by Haiying Li, senior research scientist, and Debra Schejbal, microbiology lab supervisor. The team was able to use the first in-house test just 10 days after beginning work on it, initially giving Rush the ability to test up to 87 samples a day.

A multidisciplinary team of specialists worked together through a time- and labor-intensive process to ensure the test was accurate and ready to use immediately. Once the test was created, they submitted it to the U.S. Food and Drug Administration for approval through emergency use authorization. This accelerated effort normally would have taken months to complete.

“This process and timeline was unprecedented,” said Dr. Mary Hayden, chief of the Division of Infectious Diseases and director of the Clinical Microbiology Laboratory. 

The in-house test allowed the Medical Center to perform COVID-19 testing before the release of Abbott Laboratories'​ m2000 test, which allowed for more expansive testing. The m2000 platform already was in use at Rush for molecular detection of other viruses prior to the COVID-19 pandemic, which allowed the Medical Center to transition easily to it to test for the COVID-19 virus. 

The team then adjusted their procedures, trained technicians to perform the testing and rearranged staff schedules to increase testing capacity. Once the m2000 test was in place, Rush was able to significantly increase testing to 500 samples per day.

After implementing the m2000 test, the team also began using COVID ID Now, Abbott’s point-of-care test (a test that can both be given and yield results at the time and place care is provided) and a third test, the Cepheid GeneXpert Xpress. In October, the lab installed the Alinity m, a state-of-the-art automated molecular diagnostics analyzer that nearly doubled lab capacity. Between all of these tests, the Medical Center has been able to test 6,100 people a week, allowing  it to expand testing to include  first responders

Because of their hard work, the lab’s COVID testing volume to date has increased 50% over the total test volume for the lab for last calendar year.

“This is a huge accomplishment, especially given that our staffing has not increased,” said Hayden. “The clinical microbiology staff members have worked very hard. They can feel proud that their work contributed to improved patient care and reductions in infection transmission for thousands of persons, thereby saving human lives.”

As the pandemic continues and the Chicago area experiences another, even larger COVID-19 surge than the initial wave in the spring, the microbiology team’s hard work made it possible for the Medical Center to continue large-scale testing when it’s needed most. This capacity allows patients who test positive for COVID-19 to get care earlier and those who have been exposed to them to quarantine to help reduce the spread of the virus.

“Testing will be especially important as we enter the winter respiratory virus season,” said Hayden. “It is critical so that individual patients can be treated appropriately and important for public health, to ensure that an infected person can be isolated and prevent further transmission.”

Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573